Tesla
TSLA
MicroStrategy
MSTR
MARA Holdings
MARA
Apple
AAPL
Microsoft
MSFT
US Stock MarketDetailed Quotes
ALMS Alumis
- 8.390
- -0.340-3.89%
Close Dec 13 16:00 ET
456.48MMarket Cap-1.91P/E (TTM)
8.660High8.290Low76.81KVolume8.500Open8.730Pre Close653.12KTurnover0.59%Turnover RatioLossP/E (Static)54.41MShares13.53052wk High1.31P/B110.12MFloat Cap7.66052wk Low--Dividend TTM13.13MShs Float13.530Historical High--Div YieldTTM4.24%Amplitude7.660Historical Low8.502Avg Price1Lot Size
About Alumis Company
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
Company Profile
SymbolALMS
Company NameAlumis
Listing DateJun 28, 2024
Issue Price16.00
Founded2021
CEOMr. Martin Babler
MarketNASDAQ
Employees109
Fiscal Year Ends12-31
Address280 East Grand Avenue
CitySan Francisco
ProvinceCalifornia
CountryUnited States of America
Zip Code94080
Phone1-650-231-6625
Websitehttp://www.alumis.com
Company Executives
- Name
- Position
- Salary
- Martin Babler
- Chairman of the Board, President and Chief Executive Officer
- 4.59M
- Roy C. Hardiman
- Chief Business and Legal Officer
- 1.04M
- John R. Schroer
- Chief Financial Officer
- --
- Dr. Jorn Drappa, M.D.,PhD
- Chief Medical Officer
- --
- Mark Bradley
- Chief Development Officer
- --
- Dr. David M. Goldstein, PhD
- Chief Scientific Officer
- 1.04M
- Derrick Richardson
- Senior Vice President, People and Culture
- --
- Patrick C. Machado, J.D.
- Independent Director
- --
- Dr. Zhengbin Yao, PhD
- Independent Director
- --
- Dr. Sapna Srivastava, PhD
- Independent Director
- --
- Dr. Alan B. Colowick, M.D.,M.P.H.
- Independent Director
- --
- Dr. Srinivas Akkaraju, M.D.,PhD
- Independent Director
- --
- Dr. James B. Tananbaum,M.D.
- Independent Director
- --
- Sara Klein
- General Counsel and Corporate Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
